Compare TAP & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAP | INSM |
|---|---|---|
| Founded | 1873 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 41.2B |
| IPO Year | N/A | 2000 |
| Metric | TAP | INSM |
|---|---|---|
| Price | $47.67 | $197.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 19 |
| Target Price | $51.47 | ★ $180.94 |
| AVG Volume (30 Days) | ★ 4.0M | 2.8M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,214,000,000.00 | $447,022,000.00 |
| Revenue This Year | N/A | $43.10 |
| Revenue Next Year | N/A | $128.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.34 |
| 52 Week Low | $42.94 | $60.40 |
| 52 Week High | $64.66 | $212.75 |
| Indicator | TAP | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 51.97 |
| Support Level | $44.88 | $189.59 |
| Resistance Level | $46.79 | $206.69 |
| Average True Range (ATR) | 1.07 | 6.40 |
| MACD | 0.12 | -2.76 |
| Stochastic Oscillator | 97.69 | 30.20 |
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the US, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the US, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.